Detectable Cardiac Troponin I Predicts Adverse Cardiac Events and Heart Failure Hospitalizations in Stable Heart Failure Outpatients

Abstract

months). The same institutions and physician/care teams participated in both the RCT and long-term longitudinal follow-up, thus allowing for a more clear assessment of the technology learning curve. Results: New users of the technology were able to generate robust treatment effect sizes from the RCT period for hospitalizations and mortality. With continued experience and implementation of the PAP-HF management strategy, the same users were able to replicate their initial results and generate even larger treatment effect sizes during long-term longitudinal follow-up (Table & Figure 1). Conclusions: PAP-HF management by new users of the technology resulted in significant clinical benefit in a RCT and even larger treatment effect sizes with continued experience and implementation of the PAP-HF management strategy during long-term longitudinal follow-up. These results demonstrate the absence of a steep learning curve, the durability of the treatment effects, and its applicability in the ‘real-world’ clinical setting.